Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange

Stock News

08/28

Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1148206442"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148206442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148206442?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 08:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148206442","market":"sg","top_or_hot":-1,"title":"Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange","media":"Stock News","content":"<p>Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-28 08:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1148206442","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148206442","pubTimestamp":1787876894,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","BK1574":"生物医药B类股","BK1161":"生物科技","09939":"开拓药业-B","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF","BK1515":"抗疫概念"},"translate_title":"Dizal Pharma向香港联交所重新提交H股上市申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"IPOS":1,"09939":1},"content_text":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with the corresponding listing documents posted on the HKEX website the same day. This marks the company's renewed effort to pursue a dual listing in Hong Kong after its existing A-share listing on the Shanghai Stock Exchange. The resubmission follows the company's earlier attempt, indicating its continued commitment to expanding its capital market presence and accessing international investors through the Hong Kong platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}